Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer

被引：0
|
作者：
Abraham, Jame
Mechcatie, Elizabeth
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2015年 / 13卷 / 03期
关键词：
D O I：
10.12788/jcso.0113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：83 / 86
页数：4
相关论文
共 50 条
  • [41] Real world outcomes of neoadjuvant chemotherapy in ER-positive/PR-positive, HER2-negative breast cancer
    Kurian, Matthew
    Trybula, Marcus
    Patell, Kanchi
    Guzik, Gregory
    Margevicius, Seunghee
    Fu, Pingfu
    Montero, Alberto
    Martin, James
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [43] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
    Pernas, Sonia
    Sanfeliu, Esther
    Villacampa, Guillermo
    Salvador, Javier
    Perello, Antonia
    Gonzalez, Xavier
    Jimenez, Begona
    Merino, Maria
    Palacios, Patricia
    Pascual, Tomas
    Alba, Emilio
    Villanueva, Lorea
    Chillara, Samyukta
    Ferrero-Cafiero, Juan Manuel
    Galvan, Patricia
    Prat, Aleix
    Ciruelos, Eva
    NPJ BREAST CANCER, 2024, 10 (01)
  • [44] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    L S Rigter
    C E Loo
    S C Linn
    G S Sonke
    E van Werkhoven
    E H Lips
    H A Warnars
    P K Doll
    A Bruining
    I A Mandjes
    M J Vrancken Peeters
    J Wesseling
    K G Gilhuijs
    S Rodenhuis
    British Journal of Cancer, 2013, 109 : 2965 - 2972
  • [45] Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
    da Silva, Leonardo Roberto
    de Andrade, Camila Annicchino
    Brenelli, Fabricio
    Ramalho, Susana
    Reinert, Tomas
    de Souza, Alessandra Borba Anton
    da Silva, Ana Elisa Ribeiro
    de Paula Leite Kraft, Maria Beatriz
    de Vasconcelos, Vivian Castro Antunes
    Frasson, Antonio Luiz
    Torresan, Renato Zochio
    Cabello, Cesar
    Ellis, Matthew J.
    Zeferino, Luiz Carlos
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 753 - 760
  • [46] Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
    Ho Hyun Ryu
    Sei Hyun Ahn
    Seon Ok Kim
    Jeong Eun Kim
    Ji sun Kim
    Jin-Hee Ahn
    Kyung Hae Jung
    Sung-Bae Kim
    Beom Seok Ko
    Jong Won Lee
    Byung Ho Son
    Hee Jung Shin
    Hak Hee Kim
    Gyung yub Gong
    Hee Jeong Kim
    Scientific Reports, 11
  • [47] Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
    Leonardo Roberto da Silva
    Camila Annicchino de Andrade
    Fabrício Brenelli
    Susana Ramalho
    Tomás Reinert
    Alessandra Borba Anton de Souza
    Ana Elisa Ribeiro da Silva
    Maria Beatriz de Paula Leite Kraft
    Vivian Castro Antunes de Vasconcelos
    Antônio Luiz Frasson
    Renato Zochio Torresan
    Cesar Cabello
    Matthew J. Ellis
    Luiz Carlos Zeferino
    Breast Cancer Research and Treatment, 2021, 186 : 753 - 760
  • [48] The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
    Brase, J. C.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Schmidt, M.
    Koelbl, H.
    Brauch, H.
    Schwab, M.
    Mueller, V.
    Jaenicke, F.
    Rody, A.
    Kaufmann, M.
    Filipits, M.
    Gnant, M.
    Denkert, C.
    Loibl, S.
    von Minckwitz, G.
    Kronenwett, R.
    CANCER RESEARCH, 2011, 71
  • [49] Estimating the magnitude of clinical benefit of chemotherapy in patients with early ER-positive, HER2-negative breast cancer
    McCartney, A.
    Di Leo, A.
    BREAST, 2019, 44 : S11 - S11
  • [50] Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
    Ryu, Ho Hyun
    Ahn, Sei Hyun
    Kim, Seon Ok
    Kim, Jeong Eun
    Kim, Ji Sun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Shin, Hee Jung
    Kim, Hak Hee
    Gong, Gyung Yub
    Kim, Hee Jeong
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345